@article{92553ac31fff4aef86b710a60b1f58dd,
title = "Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with aids and cytomegalovirus retinitis",
abstract = "To examine whether the prolonged survival seen in patients treated with foscarnet compared with those treated with ganciclovir was due to a direct effect on human immunodeficiency virus (HIV) replication, HIV p24 antigen was measured. Of 71 receiving foscarnet, 54% were p24 antigenpositive at enrollment (vs. 44% of 79 receiving ganciclovir). By immune complex-dissociated (ICD) p24 antigen analysis, 87% and 78%, respectively, were positive. After 1 month of treatment, there was a significant decline in standard (mean decline, 10.1 pglmL) and ICD (mean, 39.6 pg/mL) p24 antigen in both groups (P =.0001). Mortality was greater in those who were ICD p24 antigenpositive than in those -negative at baseline (P =.03) and in subjects with an increase in ICD p24 antigen than in those with a decline (P =.09). Thus, each drug had a suppressive effect on circulating p24 antigen, which was predictive of improved survival. The inhibitory effect on CMV replication may have a beneficial effect on limiting HIV replication.",
author = "{Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group} and Quinn, {Thomas C.} and Holbrook, {Janet T.} and V. Fainstein and R. Gross and T. Sarno and C. Tuttle and S. Spector and C. Ewing and T. Flynn and R. King and Holbrook, {J. T.} and Isaacson, {M. R.} and A. Kaplan-Gilipin and R. Huffman and Levine, {C. R.} and Meinert, {J. L.} and Nowakowski, {D. J.} and M. Smith and T. Tonascia and {Van Natta}, {M. L.}",
note = "Funding Information: Received 3 February 1995; revised 12 April 1995. The treatment protocol and consent procedures were reviewed and approved by the institutional review boards of the individual participating clinics, and patients gave signed, informed consent before randomization. Financial support: National Institutes of Health (EY-08052 to Johns Hopkins University School ofMedicine [Baltimore]; EY-08057 to Johns Hopkins University School of Hygiene and Public Health; EY-08067 to University of Wisconsin School of Medicine [Madison]; RR-00350 to Baylor College of Medicine [Houston]; AI-27668, RR-00035, RR-00722 to Johns Hopkins University; AI-27674, RR-05096 to Louisiana State University/Tulane; AI-27665, RR-00096 to New York University; AI-25915, RR-00048 to Northwestern University [Chicago]; AI-27660, RR-00865 to University of California, Los Angeles; AI-27663, RR-00083 to University of California, San Francisco; RR-05280 to University of Miami; AI-27669 to Memorial Sloan-Kettering Cancer Center [New York]; AI-25917 and RR-00096 to New York Hospital-Cornell Medical Center; AI-27667 to Mount Sinai Medical Center, New York; AI-27670 to University of California, San Diego; and AI-25831 to University of Massachusetts [Worcester]); Astra USA, Inc. (Westborough, MA). Drugs provided by Astra, Burroughs Wellcome (Research Triangle Park, NC), and Syntex Research (Palo Alto, CAl. Reprints: Dr. Douglas A. Jabs, Johns Hopkins University School of Medi-cinw:550 Building, Suite 700, Baltimore, MD 21205. Correspondence: Dr. Thomas C. Quinn, Division of Infectious Diseases, Johns Hopkins University, 720 Rutland Ave., Ross 1159, Baltimore, MD 21205-2196. * Group members are listed after the text.",
year = "1995",
month = sep,
doi = "10.1093/infdis/172.3.613",
language = "English (US)",
volume = "172",
pages = "613--621",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",
}